Human TACI (TNFRSF13B)
Slide this table
| Cat-Nr. | 100-285S |
| Size | 5 µg |
| Price | 95 € |
| Source | E. coli |
| Formulation | lyophilized |
| Purity Confirmation | > 98% by SDS-PAGE & HPLC analyses |
| Length [aa] | 160 |
| Molecular Weight | 17.8 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 µg/ml. |
| Species Reactivity | Human |
| Synonyms | TNFRSF13B; CVID; TACI; CD267; CVID2; TNFRSF14B |
| Description | TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI binds to both APRIL and BAFF and can stimulate the activation of transcription factors; NF-kappaB, AP-1, and mediates calcineurin dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor. Recombinant human TACI is a soluble 160 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous cysteine rich extracellular domain of the TACI protein. |
| Protein Sequence | MSGLGRSRRG GRSRVDQEER FPQGLWTGVA MRSCPEEQYW DPLLGTCMSC KTICNHQSQR TCAAFCRSLS CRKEQGKFYD HLLRDCISCA SICGQHPKQC AYFCENKLRS PVNLPPELRR QRSGEVENNS DNSGRYQGLE HRGSEASPAL PGLKLSADQV |
| Uniprot ID | O14836 |
| Protein RefSeq | NP_036584.1 |
| mRNA RefSeq | NM_012452.2 |
All prices plus VAT + possible delivery charges